BioPharma Clinical Trials

Antengene Announces Addition of Multiple XPOVIO® Treatment Regimens for Myeloma and Lymphoma in 2022 CSCO Guidelines

The 2022 CSCO Guidelines incorporate a total of four selinexor combination therapy regimens for relapsed myeloma. In addition, the guidelines also recommen...

 May 13, 2022 | News

Clinical Trial Approval For ReCOV In The PRC And The Overseas Clinical Trial Progress Of ReCOV

As disclosed in the prospectus of the Company dated March 21, 2022, the Group had initiated subject enrollment for the phase II/III clinical trial for...

 May 06, 2022 | News

Inmagene Receives FDA's IND Clearance for OX40 Antagonist

IMG-007 is highly potent at blocking the binding of OX40 to OX40L, thereby reducing OX40L-dependent downstream signaling and cytokine release by T cells. I...

 May 02, 2022 | News

Lessons Learned from COVID-19 Vaccine Trials

    IQVIA Institute releases report on Lessons Learned from COVID-19 Vaccine Trials Solutions for you to dri...

 April 28, 2022 | News

FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial

The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the FDA for an EV...

 April 28, 2022 | News

PharmAbcine Announces Positive Results for Its Novel TIE2-Activating Antibody in GLP Toxicology Study

PMC-403 can stabilize and repair damaged and pathologically leaky blood vessels, and it is being developed to treat AMD (Age-related Macular Degeneration),...

 April 27, 2022 | News

Lynk Pharmaceuticals Announces Clinical Approval in China for Its Class I New Drug LNK01004

LNK01004 is a novel kinase inhibitor that can simultaneously inhibit multiple inflammatory cytokines and block multiple signaling pathways related to psori...

 April 25, 2022 | News

TauRx's late-stage clinical trial reaches new milestone

TauRx Pharmaceuticals Ltd, a global leader in tau-based Alzheimer's Disease (AD) research, has announced that the last patient has completed treatment in t...

 April 14, 2022 | News

Seegene's Allplex™ RV Master Assay receives Australian TGA approval, European CE-IVD mark

Test detects 21 targets for 19 respiratory viruses in single tube, including COVID-19 and flu Assay result of Seegene's decades-long know-how, applies D...

 April 07, 2022 | News

CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China

Pre-clinical trial results showed that CanSinoBIO's COVID-19 mRNA vaccine can induce high-titer neutralizing antibody levels against multiple SARS-CoV-2 va...

 April 04, 2022 | News

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in Mantle Cell Lymphoma in China

Carteyva® is an anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product independently developed by JW Therapeutics. T...

 April 04, 2022 | News

eTheRNA Manufacturing Announces New LNP Formulation Development and Production Service

This new LNP service uses eTheRNA’s proprietary lipid libraries and proprietary formulations to facilitate targeted delivery and tailored biodistribu...

 March 29, 2022 | News

Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue Tablets to the Philippines

Daewoong Pharmaceutical (CEO Sengho Jeon & Changjae Lee) recently announced that it has submitted the New Drug Application (NDA) for a n...

 March 29, 2022 | News

Henlius Receives NMPA Approval for its First Innovative Monoclonal Antibody HANSIZHUANG

Furthermore, it also empowers the domestic precision immunotherapy for tumors and promotes the high-quality development of China's biopharmaceuti...

 March 28, 2022 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close